Analyst Price Target is $4.50
▲ +145.90% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ProKidney in the last 3 months. The average price target is $4.50, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 145.90% upside from the last price of $1.83.
Current Consensus is
Hold
The current consensus among 5 investment analysts is to hold stock in ProKidney. This rating changed within the last month from a Moderate Buy consensus rating.
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Read More